StreetInsider.com News Articles

Form EFFECT Milestone Pharmaceutical

Tue, 26 May 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260526/26545258.html

Form EFFECT Milestone Pharmaceutical

Tue, 26 May 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260526/26545258.html

Form SCHEDULE 13G/A Milestone Pharmaceutical Filed by: RTW INVESTMENTS, LP

Fri, 15 May 2026 08:26:00 -0400

si-local-file:///var/storage/secattach/20260515/26500016.html

Form SCHEDULE 13G/A Milestone Pharmaceutical Filed by: RTW INVESTMENTS, LP

Fri, 15 May 2026 08:26:00 -0400

si-local-file:///var/storage/secattach/20260515/26500016.html

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Thu, 14 May 2026 08:30:00 -0400

MONTREAL and CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ to take place on Tuesday, May 19, 2026 in New York.

A live webcast of the fireside chat will be available to conference participants on May 19th at 3:00pm ET. The webcast is available to watch both live and replay for approximately 90-days following the

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Thu, 14 May 2026 08:30:00 -0400

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Thu, 14 May 2026 08:30:00 -0400

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Thu, 14 May 2026 08:30:00 -0400

Milestone Pharmaceuticals (MIST) PT Lowered to $7 at Wells Fargo

Thu, 14 May 2026 06:56:52 -0400

Wells Fargo analyst Mohit Bansal lowered the price target on Milestone Pharmaceuticals (NASDAQ: MIST) to $7.00 (from $8.00) while maintaining a Overweight rating.

Form S-3 Milestone Pharmaceutical

Wed, 13 May 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260513/26487677.html

Form S-3 Milestone Pharmaceutical

Wed, 13 May 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260513/26487677.html

Form SCHEDULE 13G/A Milestone Pharmaceutical Filed by: Adage Capital Management, L.P.

Wed, 13 May 2026 09:10:00 -0400

si-local-file:///var/storage/secattach/20260513/26482956.html

Form SCHEDULE 13G/A Milestone Pharmaceutical Filed by: Adage Capital Management, L.P.

Wed, 13 May 2026 09:10:00 -0400

si-local-file:///var/storage/secattach/20260513/26482956.html

Form 8-K Milestone Pharmaceutical For: May 13

Wed, 13 May 2026 07:23:00 -0400

si-local-file:///var/storage/secattach/20260513/26481677.html

Form 8-K Milestone Pharmaceutical For: May 13

Wed, 13 May 2026 07:23:00 -0400

si-local-file:///var/storage/secattach/20260513/26481677.html

Milestone Pharmaceuticals Inc. (MIST) Misses Q1 EPS by 43c

Wed, 13 May 2026 07:17:16 -0400

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) reported Q1 EPS of ($0.20), $0.43 worse than the analyst estimate of $0.23. Revenue for the quarter came in at $238 thousand versus the consensus estimate of $56.34 million.

For earnings history and earnings-related data on Milestone Pharmaceuticals Inc. (MIST) click here.

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update